50 results about "Peroxisome" patented technology

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The invention discloses candida tropicalis engineering bacteria for high yield of (-)-alpha-bisabolol and a construction method of the candida tropicalis engineering bacteria, and belongs to the technical field of microorganisms. According to the invention, chassis cell candida tropicalis DC04-WG04-2 is constructed, a gene Cat2 of catalase derived from saccharomyces cerevisiae and a gene ERG10 of 3-hydroxy-3-methylglutaryl coenzyme A reductase are expressed on the basis of the chassis cell candida tropicalis DC04-WG04-2, and a PEX15 motif is anchored on the surface of peroxisome for co-expression; the genes ADH1, GPD1 and GPD2 are further knocked out, so that the accumulation of ethanol is reduced, and the generation of glycerol is reduced. According to the method disclosed by the invention, the yield of the (-)-alpha-bisabolol of the recombinant candida tropicalis reaches 461.7 mg / L by optimizing fermentation conditions. The preparation method has the characteristics of low cost, high efficiency, simplicity in operation, wide prospect and the like.

The invention discloses a Yarrowia lipolytica engineering bacterium for producing astaxanthin in a peroxisome compartment and application of the Yarrowia lipolytica engineering bacterium. A complete astaxanthin synthesis path is expressed in host bacteria by recombinant Yarrowia lipolytica; comprising geranyl geranyl diphosphate synthase CrtE, phytoene synthetase / lycopene cyclase CrtYB, phytoene desaturase CrtI, 3-hydroxy-3-methylglutaryl CoA reductase tHMGR, beta-carotene ketolase CrtW and beta-carotene hydroxylase CrtZ, and the enzymes are relocated into peroxisome, so that the enzyme activity of the peroxisome is improved, and the enzyme activity of the peroxisome is improved. The number of expression hemoglobin genes VHb and peroxisome is increased, the surface area of the hemoglobin genes VHb is enlarged, and one or more of enzymes PEX11, PEX19, DNM1 or PHO85 for prolonging the service life of the hemoglobin genes VHb and peroxisome is / are obtained; the astaxanthin production performance of the recombinant strain is verified based on cytoplasm engineering and subcellular organelle compartment engineering, and the astaxanthin production capacity of the yarrowia lipolytica is further improved.

Provided are a conjugate of the protein ATF6αN and peroxisomes, a use of the protein ATF6αN in the isolation and purification of peroxisomes, and a method for isolating and purifying peroxisomes by using the protein ATF6αN. The method comprises the following steps: combining a tag-ATF6αN fusion protein with a medium, so as to obtain a fusion protein-medium complex; adding a crude peroxisome sample to the fusion protein-medium complex, so as to obtain a fusion protein-medium-peroxisome complex; and adding an elution buffer and collecting an eluent, so as to obtain peroxisomes conjugated with a fusion protein.

The present invention belongs to the field of microbial metabolic engineering and synthetic biology technology applications, and particularly relates to a Pichia pastoris engineered strain that produces high sclareol production, as well as its construction method and application. A sclareol biosynthesis pathway is constructed in a host strain, and the intracellular mevalonate metabolic pathway and the central metabolic pathway are optimized, thereby obtaining an engineered bacterial strain A; the host strain is Pichia pastoris; or, metabolic regulatory factors are overexpressed or knocked out in the above-obtained engineered bacterial strain A, thereby obtaining an engineered bacterial strain B; or, in the above-obtained engineered bacterial strain B, a cell compartmentalization strategy is used to target the synthesis pathway to the peroxisome and optimize it, thereby obtaining an engineered bacterial strain C. The present invention provides a Pichia pastoris chassis cell for synthesizing the diterpenoid compound sclareol and an engineered strain for synthesizing sclareol; by introducing and optimizing the expression of the sclareol synthesis pathway, the sclareol yields in shake flask batch fermentation and bioreactor batch fed-batch fermentation reach 631.6 mg / L and 10.5 g / L, respectively.

The invention discloses a hydrogel composite material for repairing acute kidney injury as well as preparation and application thereof. The hydrogel composite material for repairing the acute kidney injury comprises peroxisome serving as an oxidative stress regulation center and self-assembly repairing polypeptide gel for encapsulating the peroxisome. According to the composite material, oxidative stress regulation is carried out through a peroxisome cascade catalytic system, a polypeptide precursor solution is initiated to be self-assembled and polymerized into gel through pH responsiveness, local drug delivery is carried out, and cell repair regulation and control of kidney injury are achieved. The problem that oxidative stress and tissue damage are difficult to solve at the same time in existing single drug treatment is solved, wound healing is accelerated by rapidly neutralizing free radicals, reducing tissue damage, activating cell proliferation and regenerating related signal channels, the composition can act on damaged tissue more accurately, the influence on healthy cells is reduced, and due to the synergistic effect mechanism, the composition has a good application prospect. More efficient and targeted kidney repair can be realized, so that remarkable advantages are shown in the repair treatment of the acute kidney injury.

The invention belongs to the technical field of bioengineering, and particularly relates to an engineering bacterium for de novo biosynthesis of cycloastragenol as well as a construction method and application of the engineering bacterium. A mevalonic acid (MVA) pathway is reconstructed in a saccharomyces cerevisiae strain peroxidase body by utilizing a cell region compartment strategy, a key enzyme gene of the MVA pathway is over-expressed by using a strong promoter, and the cycloastragenol is obtained. The key enzyme genes are used as expression elements of cycloastragenol, are introduced into the chassis saccharomyces cerevisiae through a CRISPR-Cas9 technology, and are integrated on a saccharomyces cerevisiae genome through homologous recombination, so that a saccharomyces cerevisiae engineering bacterium CycZ23 and an engineering bacterium CAG-1 for efficiently synthesizing cycloastragenol are constructed, and de novo synthesis of plant triterpenoid natural products is realized; the highest titer of the generated cycloastragenol is 236 mg / L; the synthesis method is economical, efficient, green, environmentally friendly and easy to operate, and has important application value.

The invention relates to the technical field of biology, in particular to engineered yeast for high-yield citronellol as well as a preparation method and application of the engineered yeast. According to the invention, genetically engineered bacteria for high yield of citronellol are constructed by means of genetic engineering, SyBESc081300004 is taken as an original strain, Erg20ww, Erg8, tCrGES and CrIS are expressed in a peroxisome region in a room manner, and phosphopentose pathway genes TAL1 and TKL1 and endogenous transporter protein PDR1 are over-expressed, so that the genetically engineered bacteria are obtained; experimental results show that the shake flask fermentation yield of the genetically engineered bacterium reaches 3.38 g / L, the yield of a 100L fermentation tank reaches 10.556 g / L, and the yield of the genetically engineered bacterium is obviously higher than that of other existing citronellol production engineered bacterium.

This invention discloses a lipophilic yeast strain for synthesizing astaxanthin (Yersinia lipophila). Yarrowia lipolytica This invention relates to an engineered strain, its construction method, and its application. The engineered strain is a *Yersinia lipolytica* strain carrying CrtZ and CrtW. The invention utilizes genetic engineering methods to introduce a *Yersinia lipolytica* strain derived from *Rhodochophora* into a β-carotene-producing strain via genetic engineering. Haematococcus Pluvialis The β-carotene hydroxylase encoding gene (HpCrtZ) originates from the genus Paracoccus ( Paracoccus sp. The gene encoding β-carotene ketolase (PsCrtW) and the gene derived from Saccharomyces cerevisiae (Saccharomyces cerevisiae) Saccharomyces cerevisiae The method involves obtaining a genetically engineered *Yersinia lipolytica* strain that produces astaxanthin by constructing a fusion enzyme complex and fusing it with peroxisomes, endoplasmic reticulum, and lipid droplet-targeting signal peptides to obtain a *Yersinia lipolytica* strain with higher astaxanthin yield. The astaxanthin-producing genetically engineered strain constructed in this invention achieved an astaxanthin yield of 1.43 g / L in a 5 L bioreactor after pH control and continuous feeding optimization.

The invention provides a genetic engineering strain of high-yield immunosuppressant mycophenolic acid as well as a preparation method and application of the genetic engineering strain. The invention firstly provides a method for constructing the penicillium with the effect of high yield of mycophenolic acid. The method comprises the step of replacing an indigenous promoter of acyl-coenzyme A oxidase PbACOX323 protein participating in beta oxidation in peroxisome of a penicillium strain with a promoter PgpdA of 3-phosphoglycerol dehydrogenase with an amino acid sequence of SEQ ID NO: 1. According to the method disclosed by the invention, the genetically engineered bacterium with high yield of mycophenolic acid is constructed, the yield of mycophenolic acid is positively increased by replacing a promoter of acyl-coenzyme A oxidase PbACOX323, and the method has a good industrial application value.

The contents disclosed herein include methods, compositions, and kits suitable for use in enhanced adoptive T cell therapy. In some embodiments, the methods include contacting an isolated organelle complex with a population of T cells to produce a population of T cells comprising the organelle complex. The organelle complex can include mitochondria and one or more of endoplasmic reticulum, peroxisome, lysosome, and Golgi. The population of T cells exhibits one or more of the following: enhanced expansion capability, enhanced cytotoxicity against a target cell, enhanced resistance to depletion, and enhanced persistence compared to a population of T cells not comprising an exogenous organelle complex.

The invention discloses a saccharomyces cerevisiae strain with high yield of campesterol as well as a construction method and application of the saccharomyces cerevisiae strain. One of the key rate-limiting enzymes, which are heterologously synthesized in the yeast, of the campesterol ((24R)-Ergosta-5-en-3beta-ol) is from a plant C-24 (28) reductase DWF1 mutant (Ar207). In view of the characteristics that the catalytic activity of the enzyme is relatively low and substrates are dispersedly distributed in different compartments of cells, on the basis of the original recombinant saccharomyces cerevisiae for producing campesterol, a rate-limiting enzyme gene copy positioned to a specific subcellular organelle is additionally added, so that the campesterol can be produced. The expression quantity is effectively increased; meanwhile, the contact between the enzyme and a substrate in a corresponding chamber is enhanced; and the yield of campesterol is increased. By utilizing the strategy, Ar207 is positioned to recombinant bacteria of peroxisome and lipid droplets, and the yield of campesterol reaches 3.00 g / l and 3.77 g / l respectively during fermentation in a 5L tank.

The present invention relates to decanoic acid and a composition comprising the same for use in the treatment and / or prevention of peroxisome disorders.

This invention belongs to the field of microbial metabolic engineering and biotechnology applications, specifically relating to an engineered bacterium for synthesizing monoterpenoid compounds, its construction method, and its applications. The construction method involves using *Hansenula polymorpha* as a host, regulating the mevalonate pathway in its cytoplasm, and overexpressing monoterpene synthase to obtain the engineered bacterium; or, overexpressing monoterpene synthase and the mevalonate pathway in peroxisomes to obtain the engineered bacterium. The engineered bacterium constructed in this application can efficiently synthesize monoterpenoid compounds such as geraniol, β-myrcene, and dextrorotatory borneol.

Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and / or peroxisomal function.

The invention relates to the technical field of microorganisms, and discloses recombinant yeast for efficiently synthesizing a GPP derivative compound as well as a construction method and application of the recombinant yeast. The recombinant yeast strain takes a yeast strain as an original strain, and is obtained by introducing a target coding gene into a cell nucleus; the target coding gene comprises a coding gene of a mevalonic acid (MVA) synthetic pathway enzyme, a coding gene of a farnesyl diphosphate synthase mutant and a coding gene of optional geranyl diphosphate derivative synthase. According to the invention, an MVA pathway and a key enzyme are introduced into a cell nucleus, so that competitive consumption of a sterol synthesis pathway in cytoplasm on geranyl diphosphate (GPP) is effectively avoided, and efficient synthesis of the GPP derivative compound is realized. Besides, the recombinant yeast strain disclosed by the invention can be combined with a reported peroxisome platform to construct a double-organelle platform strain, so that the yield of GPP derivative compounds can be further increased.

The invention discloses a recombinant Yarrowia lipolytica engineering strain for producing abscisic acid and application of the recombinant Yarrowia lipolytica engineering strain, and belongs to the technical field of genetic engineering and bioengineering. According to the invention, heterologous synthesis of ABA is realized in the Yarrowia lipolytica, precursor supply is optimized by enhancing carbon flow in a metabolic pathway, the activity of key enzymes BcABA2 and BcABA3 is improved by adopting a semi-rational strategy, NADPH regeneration engineering is implemented to enhance the oxygen uptake ability of a strain, a cytoplasm-peroxisome engineering system is constructed, and the oxygen uptake ability of the strain is enhanced. The ABA synthesis is further enhanced by utilizing the characteristic of high-yield acetyl coenzyme A of peroxisome. According to the invention, fermentation conditions are further optimized, so that the ABA accumulation concentration of the constructed engineering strain in a 5 L bioreactor reaches 2554.36 mg / L, and the highest titer of ABA biosynthesis reported so far is created. The metabolic modification strategy provides important reference for biosynthesis of other terpenoids.

Disclosed herein include organelle complexes populations. The organelle complexes can comprise mitochondria and one or more of endoplasmic reticulum, peroxisomes, lysosomes, and Golgi apparatus. In some embodiments, the organelle complexes are isolated or derived from floating cells and / or frozen cells. In some embodiments, the organelle complexes are isolated or derived from cells contacted with a surfactant at a concentration at or above the critical micellar concentration (CMC) for the surfactant. At least about 80% of the mitochondria of the organelle complexes are capable of maintaining structural integrity in an extracellular environment. Also provided herein are methods for generating first organelle complexes populations.

The invention relates to the technical field of microorganisms, and particularly discloses recombinant saccharomycetes and application thereof in fermentation production of beta-elemene. Compared with a starting yeast strain, the recombinant yeast provided by the invention expresses farnesyl diphosphate synthase ERG20, sesquiterpene synthase LsLTC2 from lettuce and difunctional farnesyl diphosphate synthase RrFPS from rose, and expresses IDI1, ERG13, ERG8, ERG10, ERG12, MVD1 and tHMGR in peroxisome. Preferably, the expression quantity of squalene synthase ERG9 in a cell matrix is further reduced, ERG10, ERG13 and IDI1 are overexpressed, and XFPK, PTA, POXB and ACS are expressed. The recombinant saccharomycetes disclosed by the invention can efficiently produce the beta-elemene, and a more effective method is provided for industrial production of the beta-elemene.

The present invention discloses a genetically engineered Schizochytrium strain for efficient DHA production, as well as a construction method and application. The genetically engineered strain is obtained by knocking out the peroxisome matrix protein gene PEX10 in the wild-type Schizochytrium, which disrupts the β-oxidation pathway and blocks the degradation of fatty acyl-CoA; overexpressing the acetyl-CoA carboxylase gene ACC1 to provide more malonyl-CoA precursors, thereby promoting fatty acid biosynthesis; and overexpressing the diacylglycerol acyltransferase gene DGAT to promote the accumulation of fatty acids in the form of triglycerides. Under shake flask conditions, after fermentation, the DHA and PUFA produced reached 55.10% and 70.47% of the total oil content, respectively. Compared with the wild-type strain, DHA and PUFA increased by 21.6% and 24.77%, respectively, without a significant change in biomass, showing extremely high application potential.

The invention relates to the fields of biochemical engineering, synthetic biology and biological medicine, in particular to a gemmarene A synthetase mutant, a fusion protein, an engineering strain and application. According to the invention, the GASX-L1H2H3V436LH4 with the highest catalytic activity is successfully obtained by means of point mutation and structural domain substitution; compared with wild type LTC2 and HaGAS1, the enzyme has the advantages that the catalytic activity is obviously improved, the fusion protein HaGAS1GGGSERG20 is constructed through a flexible linker, and the beta-elemene synthesis efficiency is further improved; on the basis, by strengthening a cytoplasm MVA pathway and constructing a peroxisome MVA pathway, intracellular precursor substances and acetyl coenzyme A are fully utilized, and the yield of elemene is further increased; on the basis, genes related to grease metabolism are screened to find overexpressed TGL4, and the shake flask yield of elemene is further increased.

The invention discloses a recombinant bacterium and application thereof in production of triptolic acid C or a precursor friedelin thereof. The recombinant strain expresses a gene TwOSC1T502E for synthesizing a tripterygium wilfordii C precursor friedelin, so that de novo synthesis of friedelin is realized, and the yield of the precursor friedelin is increased through MVA (Mycopoeic Acid) pathway optimization and peroxisome metabolism-form collaborative optimization; the method comprises the following steps: by taking tripterygium wilfordii as a raw material, firstly synthesizing tripterygium wilfordii in saccharomyces cerevisiae, then expressing tripterygium wilfordii C synthesis related genes ThCYP712K1 and TrCYP716C52 and TwCPR3, realizing de novo synthesis of tripterygium wilfordii C in saccharomyces cerevisiae, obtaining the ThCYP712K1 mutant ThCYP712K1I124V with improved activity through enzyme engineering, and remarkably improving the yield of tripterygium wilfordii C through lipid droplet engineering modification and cofactor engineering modification. The recombinant strain provided by the invention can be used for efficiently producing the triptolide C and the precursor friedelin of the triptolide C, and has an important application value.

Disclosed herein include methods, compositions, and kits suitable for use in enhancing adoptive T cell therapy. In some embodiments, the method comprises contacting isolated organelle complexes with a population of T cells to generate a population of T cells comprising the organelle complexes. The organelle complexes can comprise mitochondria and one or more of endoplasmic reticulum, peroxisomes, lysosomes, and Golgi apparatus. The population of T cells can exhibit one or more of enhanced expansion capability, enhanced cytotoxicity against target cells, enhanced resistance to exhaustion, and enhanced persistence, as compared to a population of T cells that do not comprise exogenous organelle complexes

The invention discloses kluyveromyces marxianus genetically engineered bacteria and application thereof, and belongs to the technical field of bioengineering. The invention discloses a kluyveromyces marxianus genetically engineered bacterium. The kluyveromyces marxianus genetically engineered bacterium is prepared by the following steps: firstly, screening to obtain a kluyveromyces marxianus strain with high ergosterol yield; on the basis, inducing and separating a MATa haploid strain; then, through the introduction of heterologous DHCR24 and DWF5 genes, the weakening of a competitive pathway gene ERG6, the improvement of the metabolic flux of a squalene pathway in a sterol synthesis process, the compartment engineering of a peroxisome region of a mevalonic acid pathway, the knockout of an hypoxia inhibition transcription factor ROX1, the improvement of cofactor supply, the optimization of a yeast lipid pathway and other metabolic engineering optimization reconstructions, the expression of the yeast lipid pathway is improved; and an engineering strain with high cholesterol yield is constructed and obtained. Through fed-batch fermentation, efficient and stable synthesis of cholesterol is achieved, the yield reaches 7.64 g / L, and a foundation is laid for biological manufacturing of cholesterol.

The invention relates to the technical field of medical research, in particular to a method for promoting fatty acid degradation and delaying AKI-CKD conversion, which comprises the following steps: a key link of AKI-CKD conversion: peroxisome fatty acid oxidation; the method comprises the following steps of: promoting AKI-CKD transformation by injury of renal tubular epithelial cells (Proximal Tubular Cells, PTCs), and promoting AKI-CKD transformation by injury of the PTCs; the peroxisome FAO affects energy metabolism in PTCs repair; the peroxisome FAO plays a key role in delaying AKI-CKD conversion, and exploration of a regulation and control network mechanism of the peroxisome FAO is very necessary. The application has the advantages that the effect of peroxisome FAO in conversion is focused from the progress characteristic of the AKI-CKD disease, the inhibition of XOR can regulate and control the peroxisome FAO by promoting ABCD3, the regulation and control effect of XOR is preliminarily verified, and a theoretical foundation is laid for subsequently exploring the regulation and control mechanism of XOR; the research preliminarily proves that XOR plays an important role in AKI-CKD disease progression by regulating peroxisome FAO, and provides a new perspective for deeply understanding the pathogenesis of AKI-CKD.

Method and compositions for producing malonyl-CoA and / or triacetic acid lactone within peroxisomes using genetically modified yeast cells to metabolize a substrate containing fatty acids, vegetable oil, or alkanes, and genetically modified organisms are provided. Also provided are methods to generate acetyl-CoA, which is retained in the peroxisomes due to genetic modifications that prevent its export therefrom. A modified enzyme with a peroxisomal targeting sequence catalyzes a reaction between acetyl-CoA and oxaloacetate, producing pyruvate and malonyl-CoA. The methods can include deleting carnitine acetyltransferase (CAT2) alleles to prevent acetyl-CoA export from peroxisomes, and using genes encoding methylmalonyl-CoA carboxyltransferase subunits with peroxisomal targeting sequences. Additionally, the method incorporates 2-pyrone synthase genes to further facilitate production processes.

The invention discloses a candida tropicalis engineering bacterium for producing astaxanthin, and belongs to the field of metabolic engineering. Candida tropicalis ANT-06 is used as a starting strain to integrally express a heterologous gene CrtZ and a gene CrtW, the heterologous gene CrtZ and the gene CrtW are subjected to fusion expression with a peroxisome signal peptide ePTS and a lipid droplet signal peptide HD2, and the yield of astaxanthin can be obviously increased through a combined strategy of knocking out a phosphatidic acid phosphatase gene PAH1 and a functional homolog gene FLD1 of human seipin. And after combined fermentation optimization, fermentation culture at 22 DEG C and addition of 10% of dodecane, 2.5% of DMSO and 2.5 mM of betaine, the shake flask fermentation yield of the astaxanthin is increased to 320.1 mg / L, and the amplification fermentation yield of a 5L fermentation tank is increased to 3096.2 mg / L. The preparation method has the characteristics of low cost, high efficiency, simplicity in operation, wide prospect and the like.

Strains of yeasts are provided containing the genes for the production of cannabinoids from fatty acids. The enzymes that mediate cannabinoid production are localized to the cytosol, peroxisome or different compartments within the secretory pathway (e.g., endoplasmic reticulum, Golgi, vacuole) to ensure efficient production. The engineered microorganisms produce cannabinoids in a controlled fermentation process.

The invention provides a method for biologically synthesizing 1 ', 4'-trans-abscisic acid diol by utilizing yarrowia lipolytica. According to the invention, a strain of recombinant yarrowia lipolytica capable of producing the abscisic acid at high yield is used as a chassis cell, and the synthesis of the 1 ', 4'-trans-abscisic acid glycol to the abscisic acid is blocked by knocking out sesquiterpene dehydrogenase BcAba4 in the chassis cell, so that the yarrowia lipolytica capable of producing the 1 ', 4'-trans-abscisic acid glycol is obtained; a citric acid transporter 1 coding gene CEX1 is further knocked out, ATP citric acid lyase coding genes ACL1 and ACL2, a peroxisome carnitine acetyltransferase coding gene CAT2, lipase coding genes TGL3 and TGL4 and a peroxisome multifunctional enzyme coding gene MFE1 are overexpressed, and an ERG9 gene promoter is replaced by a growth dependent promoter PD19. The supply of the precursor acetyl CoA is improved, the path of the precursor acetyl CoA to grease synthesis is reduced, the metabolic flux from FPP to squalene is reduced, and the accumulation capacity of 1 ', 4'-trans-abscisic acid diol in the recombinant bacteria is improved.

The present invention discloses a preparation method and application of artificial peroxisomes LOX-Ce6-Mn; belonging to the field of nanomaterials and tumor treatment technology, the preparation steps are: firstly uniformly mixing prepared DCC, NHS, Ce6, and LOX in proportion, dialyzing with a dialysis bag after the reaction, adding an aqueous solution of MnCl2, adjusting the pH value, dialyzing, and drying to obtain LCM nanoparticles. In the present invention, the lactate oxidase activity, oxidase activity (OXD), peroxidase activity (POD), and catalase activity (CAT) of the LCM nanoparticles can constitute a cascade reaction, causing tumor cells to produce efficient reactive oxygen and consume intratumoral lactate and glutathione, causing tumor cells to undergo autophagy and apoptosis; in addition, the H2O2 catalyzed by LOX can be transported by Mn 2+ The mediated Fenton-like reaction converts hydroxyl radicals into highly toxic free radicals, further amplifying the oxidative damage of cancer cells. LCM nanoparticles are tumor-specific in killing tumor cells, effectively accumulating in tumor sites, with little killing effect on normal sites, and have good biocompatibility.